These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8804334)

  • 1. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.
    Antoniazzi F; Bertoldo F; Mottes M; Valli M; Sirpresi S; Zamboni G; Valentini R; Tató L
    J Pediatr; 1996 Sep; 129(3):432-9. PubMed ID: 8804334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
    Marini JC; Hopkins E; Glorieux FH; Chrousos GP; Reynolds JC; Gundberg CM; Reing CM
    J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
    Lanes R; Gunczler P; Esaa S; Weisinger JR
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters.
    Cepollaro C; Gonnelli S; Pondrelli C; Montagnani A; Martini S; Bruni D; Gennari C
    Calcif Tissue Int; 1999 Aug; 65(2):129-32. PubMed ID: 10430645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta.
    Minisola S; Piccioni AL; Rosso R; Romagnoli E; Pacitti MT; Scarnecchia L; Mazzuoli G
    Metabolism; 1994 Oct; 43(10):1261-5. PubMed ID: 7934978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.
    Bergmann P; Valsamis J; Van Perborgh J; De Schepper J; Van Vliet G
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1461-7. PubMed ID: 2229302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.
    Beshyah SA; Kyd P; Thomas E; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):249-54. PubMed ID: 7758229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
    Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G
    J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
    Crofton PM; Stirling HF; Schönau E; Kelnar CJ
    Clin Endocrinol (Oxf); 1996 Apr; 44(4):385-94. PubMed ID: 8706304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism.
    Beshyah SA; Thomas E; Kyd P; Sharp P; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):383-91. PubMed ID: 8187303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy.
    Thorsen K; Kristoffersson AO; Lorentzon RP
    Surgery; 1997 Nov; 122(5):882-7. PubMed ID: 9369887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
    Folkestad L
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.
    Kotzmann H; Riedl M; Bernecker P; Clodi M; Kainberger F; Kaider A; Woloszczuk W; Luger A
    Calcif Tissue Int; 1998 Jan; 62(1):40-6. PubMed ID: 9405732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.
    Glorieux FH; Devogelaer JP; Durigova M; Goemaere S; Hemsley S; Jakob F; Junker U; Ruckle J; Seefried L; Winkle PJ
    J Bone Miner Res; 2017 Jul; 32(7):1496-1504. PubMed ID: 28370407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.